Cara Therapeutics (CARA) Tops Q4 EPS by 6c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
• Vireo Growth completes acquisition of C21 Investments